P1-143 - Outcome of progestin therapy in patients with endometrial cancer recurrence

Abstract

Objective: The aim of this study was to elucidate the efficacy of progestin therapy in patients with endometrial cancer recurrence. Methods: Patients who received 200 mg/day of oral medroxyprogesterone acetate (MPA) therapy for endometrial cancer recurrence at our hospital between 2005 and 2016 were retrospectively recruited. Patients who had no target lesion and discontinued MPA within one month were excluded from the analysis. The association of clinicopathological factor with response rate to MPA and progression free survival (PFS) was examined. Results: Seven patients were examined. The median duration of MPA administration was 12.4 months. The complete response was observed in no patient, partial response in 2 patients, stable disease in 3 patients, and progressive disease in 2 patients. The response rate was 28.6% and the median PFS was 9.2 months (range: 1-26.7 months). The adverse events including thrombosis were absent. In two patients with partial response, the histological type was endometrioid carcinoma and the relapse site was lung. However, in two patients with progression disease, the histological types were serous and endometrioid carcinoma, both cases of estrogen receptor-negative, and the relapse sites were peritoneal dissemination and bone. Conclusion: This study suggested that while the effect of progestin therapy was limited on patients with endometrial cancer recurrence, there were some cases where progestin therapy could control the disease progression without side effects for a long time.